ALECTOR INC. - COMMON STOCK

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

29 7 2021 09:10:00 提供 Nasdaq GlobeNewswire

Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference

21 7 2021 15:35:14 提供 Nasdaq GlobeNewswire

Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases

02 7 2021 06:38:44 提供 Nasdaq GlobeNewswire

Alector to Present at Upcoming Virtual Healthcare Conferences

03 6 2021 15:05:00 提供 Nasdaq GlobeNewswire

Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021

26 5 2021 15:05:00 提供 Nasdaq GlobeNewswire

Alector to Present at the BofA Securities 2021 Virtual Health Care Conference

06 5 2021 15:05:01 提供 Nasdaq GlobeNewswire

Alector Reports 2021 First Quarter Financial Results and Provides Business Update

05 5 2021 15:05:01 提供 Nasdaq GlobeNewswire

Alector to Present at Stifel’s 3rd Annual CNS Day

25 3 2021 15:05:00 提供 Nasdaq GlobeNewswire

Alector to Present at the Barclays Global Healthcare Conference

04 3 2021 15:05:01 提供 Nasdaq GlobeNewswire

Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update

25 2 2021 15:05:00 提供 Nasdaq GlobeNewswire

Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease

25 1 2021 07:30:00 提供 Nasdaq GlobeNewswire

Alector Announces Departure of Chief Business Officer

20 1 2021 15:15:00 提供 Nasdaq GlobeNewswire

Alector Provides 2021 Corporate Portfolio Update

07 1 2021 15:05:00 提供 Nasdaq GlobeNewswire